Search Results - "van der Horst‐Bruinsma, I. E."

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal by Rudwaleit, M, Landewé, R, van der Heijde, D, Listing, J, Brandt, J, Braun, J, Burgos-Vargas, R, Collantes-Estevez, E, Davis, J, Dijkmans, B, Dougados, M, Emery, P, van der Horst-Bruinsma, I E, Inman, R, Khan, M A, Leirisalo-Repo, M, van der Linden, S, Maksymowych, W P, Mielants, H, Olivieri, I, Sturrock, R, de Vlam, K, Sieper, J

“…Non-radiographic axial spondyloarthritis (SpA) is characterised by a lack of definitive radiographic sacroiliitis and is considered an early stage of…”
Get more information

Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis by Nielen, M M J, van Schaardenburg, D, Reesink, H W, Twisk, J W R, van de Stadt, R J, van der Horst-Bruinsma, I E, de Koning, M H M T, Habibuw, M R, Dijkmans, B A C

“…Objective: To investigate the temporal relationship between onset of inflammation (as measured by secretory phospholipase A2 (sPLA2) and C reactive protein…”
Get full text

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis by de Vries, M K, van der Horst-Bruinsma, I E, Nurmohamed, M T, Aarden, L A, Stapel, S O, Peters, M J L, van Denderen, J C, Dijkmans, B A C, Wolbink, G J

“…Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to…”
Get more information

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis by van Halm, V P, Nielen, M M J, Nurmohamed, M T, van Schaardenburg, D, Reesink, H W, Voskuyl, A E, Twisk, J W R, van de Stadt, R J, de Koning, M H M T, Habibuw, M R, van der Horst–Bruinsma, I E, Dijkmans, B A C

“…Background: Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk. It was recently shown that active early rheumatoid…”
Get full text

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis by Heslinga, S C, Konings, T C, van der Horst-Bruinsma, I E, Kamp, O, van Halm, V P, de Bruin-Bon, Hacm, Peters, M J, Nurmohamed, M T

“…Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking…”
Get full text

CARD15 gene mutations are not associated with ankylosing spondylitis by VAN DER PAARDT, M, CRUSIUS, J. B. A, DE KONING, Mhmt, MURILLO, L. S, VAN DE STADT, R. J, DIJKMANS, S. A. C, PENA, A. S, VAN DER HORST-BRUINSMA, I. E

“…An insertion mutation at nucleotide 3020 (3020insC) and a missense mutation G2722C in the CARD15 gene on chromosome 16p have been reported to be associated…”
Get full text

Study on the Protective Effect of the KIR3DL1 Gene in Ankylosing Spondylitis by Vendelbosch, S., Heslinga, S. C., John, M., van Leeuwen, K., Geissler, J., de Boer, M., Tanck, M. W. T., van den Berg, T. K., Crusius, J. B. A., van der Horst‐Bruinsma, I. E., Kuijpers, T. W.

“…Objective Ankylosing spondylitis (AS) is an autoimmune disease that mainly affects the sacroiliac joints and the spine of the lower back. The disease is…”
Get full text

Statin therapy might be beneficial for patients with ankylosing spondylitis by van Denderen, J C, Peters, M J L, van Halm, V P, van der Horst-Bruinsma, I E, Dijkmans, B A C, Nurmohamed, M T

“…[...]as AS is associated with an increased cardiovascular risk, 5 the use of statins might ultimately lead to reduction of this risk by two pathways: one…”
Get full text

Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis by van Halm, V P, van Denderen, J C, Peters, M J L, Twisk, J W R, van der Paardt, M, van der Horst-Bruinsma, I E, van de Stadt, R J, de Koning, M H M T, Dijkmans, B A C, Nurmohamed, M T

“…Background: Cardiovascular mortality is increased in patients with ankylosing spondylitis. A possible explanation might be a more prevalent atherogenic lipid…”
Get full text

Evidence for a protective role of the human leukocyte antigen class II region in early rheumatoid arthritis by Vos, K., van der Horst‐Bruinsma, I. E., Hazes, J. M. W., Breedveld, F. C., le Cessie, S., Schreuder, G. M. Th, de Vries, R. R. P., Zanelli, E.

“…Objective. To analyse the distribution of predisposing DQ3 (DQB1*03(*04)/DQA1*03) and DQ5 (DQB1*0501/DQA1*01), shared epitope encoding and protective DRB1…”
Get full text

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study by Bos, W H, Wolbink, G J, Boers, M, Tijhuis, G J, de Vries, N, van der Horst-Bruinsma, I E, Tak, P P, van de Stadt, R J, van der Laken, C J, Dijkmans, B A C, van Schaardenburg, D

“…Anti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis. To investigate the effect of the presence and levels…”
Get more information

Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis by van Denderen, J C, van der Paardt, M, Nurmohamed, M T, de Ryck, Y M M A, Dijkmans, B A C, van der Horst-Bruinsma, I E

“…Objective: To assess the efficacy and safety of leflunomide in active ankylosing spondylitis (AS) compared with placebo in a 24 week pilot study. Methods: In a…”
Get full text

The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study by Swart, I. A. P., Visman, I. M., Heslinga, M., van der Horst-Bruinsma, I. E., van Denderen, J. C., Nurmohamed, M. T.

“…Background Biologicals, such as anti-tumor necrosis factor (anti-TNF), reduce cardiovascular disease (CVD) in patients with inflammatory rheumatic diseases…”
Get full text

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation by de Vries, M K, Wolbink, G J, Stapel, S O, de Groot, E R, Dijkmans, B A C, Aarden, L A, van der Horst-Bruinsma, I E

“…Table 1 Clinical reponse to infliximab in patients with ankylosing spondylitis in relation to infliximab levels and antibodies to infliximab after 24 weeks…”
Get full text

Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation by Baniaamam, M., Heslinga, S. C., Konings, T. C., Handoko, M. L., Kamp, O., van Halm, V. P., van der Horst-Bruinsma, I. E., Nurmohamed, M. T.

“…To assess the association between the aortic root diameter in HLA-B27 positive (+) and HLA-B27 negative (−) ankylosing spondylitis (AS) patients from the…”
Get full text

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis by van den Oever, I. A. M., Baniaamam, M., Simsek, S., Raterman, H. G., van Denderen, J. C., van Eijk, I. C., Peters, M. J. L., van der Horst-Bruinsma, I. E., Smulders, Y. M., Nurmohamed, M. T.

“…Given the link between systemic inflammation, body composition and insulin resistance (IR), anti-inflammatory therapy may improve IR and body composition in…”
Get full text

Predictors of radiographic joint damage in patients with early rheumatoid arthritis by Jansen, L M A, van der Horst-Bruinsma, I E, van Schaardenburg, D, Bezemer, P D, Dijkmans, B A C

“…OBJECTIVE To determine factors at diagnosis, associated with radiographic damage at diagnosis and after one year, in patients with early rheumatoid arthritis…”
Get full text

The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis by Dik, VK, Peters, MJL, Dijkmans, PA, Van der Weijden, MAC, De Vries, MK, Dijkmans, BAC, Van der Horst-Bruinsma, IE, Nurmohamed, MT

“…Objectives: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk. Conduction disturbances (CD) may explain the CV burden, as…”
Get full text

ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health by Boonen, A, Braun, J, van der Horst Bruinsma, I E, Huang, F, Maksymowych, W, Kostanjsek, N, Cieza, A, Stucki, G, van der Heijde, D

“…To report on the results of a standardised consensus process agreeing on concepts typical and/or relevant when classifying functioning and health in patients…”
Get more information

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study by Rusman, T, Nurmohamed, MT, Hoekstra, S, van Denderen, CJ, van Vollenhoven, RF, Boers, M, Ter Wee, MM, van der Horst-Bruinsma, IE

“…To assess sex differences in response, level of disease activity, and drug survival in tumour necrosis factor inhibitor (TNFi)-naïve ankylosing spondylitis…”
Get full text